Lotus Tissue Repair
Cambridge
About Lotus Tissue Repair
Lotus Tissue Repair is developing its proprietary recombinant human collagen Type VII (rC7) technology as a treatment for dermatologic conditions in which rC7 may play an important role in accelerating chronic wound healing, such as diabetic foot ulcers, venous stasis ulcers and similar conditions.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $26.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2011)
- Website: lotustissuerepair.com
- Phone: +1 617-674-7610
Industries & Categories
Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/lotus-tissue-repair-2417970 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.